PRC SAMR Merger Control: A Quick Reference for Non-PRC Counsel

For lawyers running a cross-border deal that touches mainland China, China's merger control regime is rarely the most exotic part of the timeline — but it is often the part that most reliably blows up a closing schedule when handled badly. This note is a working orientation, not a substitute for PRC counsel. Where a real filing is in scope, please involve qualified PRC antitrust counsel from the term-sheet stage.

The regulator and the rules

Merger control sits with the State Administration for Market Regulation (SAMR), specifically its Anti-Monopoly Bureau. The substantive rules live in the Anti-Monopoly Law (AML) and a layered set of implementing regulations and SAMR guidance. Two pieces of background matter:

• The AML was substantially revised in 2022, raising statutory penalties and tightening procedure.
• Turnover thresholds were updated in 2024, materially raising the figures that trigger a filing. Older diligence checklists may still cite pre-2024 numbers — verify against current SAMR guidance.

Practitioners should be aware that several deals which would have triggered filings under the older thresholds may not under the current ones, and vice versa for certain digital-economy structures.

When a filing is required

A filing is mandatory when the transaction is a concentration within the meaning of the AML and the parties' turnover meets the prescribed thresholds. The two tests run in parallel.

Concentration

A concentration includes:

• a merger between undertakings;
• one undertaking acquiring control over another, by equity, assets, contract or otherwise;
• the establishment of a joint venture by two or more undertakings.

"Control" is functional rather than formal. Minority stakes can constitute acquisition of control where they confer veto rights over budget, business plan, senior management or other key matters. Counsel should not assume that a sub-50% stake is automatically outside scope.

Turnover

Both of the following must be true to trigger a filing:

• the parties' global combined turnover in the preceding financial year exceeded the global threshold; or their China combined turnover exceeded the domestic threshold; and
• at least two parties each had China turnover exceeding the per-party threshold.

The precise figures should be checked against the current SAMR notification before filing — they have moved in living memory and may move again. The qualitative point: small foreign-to-foreign deals with minimal China nexus are typically out of scope; deals with multiple parties each having meaningful China revenue are typically in scope.

Simple-case procedure vs ordinary procedure

SAMR operates a simple-case procedure designed to clear competitively benign transactions faster. Eligibility is set by a separate set of criteria — broadly, deals where the parties' combined market share is below specified levels in any relevant market, where the joint venture does not operate in China, or where the transaction is internal restructuring.

When a deal qualifies for the simple case:

• Filing materials are lighter (though not trivial).
• Review is generally completed within Phase I (30 calendar days from acceptance).
• A public summary is posted on the SAMR website during a public-comment window.

When a deal does not qualify, expect the ordinary procedure: Phase I (30 days), with possible extensions to Phase II (90 additional days) and Phase III (60 additional days). Complex deals can stretch six months or more before unconditional clearance.

Common traps for non-PRC counsel

Several issues surface repeatedly in deals where the PRC-side filing was treated as an afterthought.

1. Acceptance is not filing. The statutory review clock starts when SAMR formally accepts the filing as complete, not when it is submitted. Several rounds of supplementation can sit between submission and acceptance, particularly for deals SAMR finds substantively interesting. Build a realistic acceptance buffer into the SPA timeline.

2. Information requests will outlast your retention plan. Phase II and Phase III deals routinely require detailed market data, internal strategic documents, competitor maps, and meetings. The deal team that produced the term sheet is often no longer the team that closes the deal. Plan for continuity.

3. Gun-jumping. Implementing the transaction before clearance is unlawful and triggers turnover-based penalties under the revised AML. Information-sharing during integration planning needs a clean-room protocol; sharing competitively sensitive data outside such a protocol is itself problematic. The risk is real and has resulted in published penalty decisions.

4. Below-threshold but reportable. SAMR retains the power to call in transactions that fall below the thresholds if it considers they may have anti-competitive effects. Counsel should not treat below-threshold status as a safe harbour for deals with obvious competition concerns.

5. JV's China presence. A joint venture established outside China can still trigger a Chinese filing if it will have any turnover, sales or business activity in China. The location-of-incorporation test will mislead non-PRC counsel; the location-of-activity test is what matters.

A practical checklist at term-sheet stage

Run through these questions before the term sheet is signed:

#	Question	If yes
1	Does either party have material China turnover?	Engage PRC counsel for a threshold analysis
2	Will the JV / acquired business operate in China?	Filing likely in scope, simple-case test next
3	Are the parties active in overlapping markets in China?	Simple case may not be available
4	Are there minority veto rights that may amount to control?	Concentration analysis required
5	Is the transaction part of a wider, staged integration?	Gun-jumping risk needs a clean-room protocol

Closing

China merger control is not where you discover surprises in week 11 of a 12-week SPA. The two practical asks are simple: get the PRC turnover analysis done early, and build the simple-case-vs-ordinary determination into the timeline up front. The rest is execution.

---

This article is general commentary on Chinese merger-control practice as of the date above. It is not legal advice and does not address the specifics of any particular transaction. For matters governed by PRC law, please engage qualified PRC counsel.